ArticleThe Journal of experimental medicine1989
Mouse macrophage hemagglutinin (sheep erythrocyte receptor) with specificity for sialylated glycoconjugates characterized by a monoclonal antibody.
Article in The Journal of experimental medicine, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 250 citations in OpenAlex.
- Type I interferon-induced CD169Journal of periodontology · 2026Article
- CD169Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Exploring CD169Vaccines · 2025Review
- Elucidation of the Binding Orientation in α2,3- and α2,6-Linked Neu5Ac-Gal Epitopes toward a Hydrophilic Molecularly Imprinted Monolith.ACS omega · 2023Article
- Review
- CD169-CD43 interaction is involved in erythroblastic island formation and erythroid differentiation.Haematologica · 2023Article
- Age-dependent differences in efferocytosis determine the outcome of opsonophagocytic protection from invasive pathogens.Immunity · 2023Article
- Sialoadhesin (CD169/Siglec-1) is an extended molecule that escapes inhibitory cis-interactions and synergizes with other macrophage receptors to promote phagocytosis.Glycoconjugate journal · 2023Article
- Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.Frontiers in immunology · 2022Review
- HIV-1Pathogens (Basel, Switzerland) · 2021Review
- Siglecs at the Host-Pathogen Interface.Advances in experimental medicine and biology · 2020Review
- Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model.Frontiers in immunology · 2020Article
- Erythroblast island macrophages: recent discovery and future perspectives.Blood science (Baltimore, Md.) · 2019Article
- CD4Frontiers in immunology · 2018Article
- Viewing Siglecs through the lens of tumor immunology.Immunological reviews · 2017Review
- From the Cradle to the Grave: The Role of Macrophages in Erythropoiesis and Erythrophagocytosis.Frontiers in immunology · 2017Review
- Unraveling Macrophage Heterogeneity in Erythroblastic Islands.Frontiers in immunology · 2017Article
- Expression of Siglec-E Alters the Proteome of Lipopolysaccharide (LPS)-Activated Macrophages but Does Not Affect LPS-Driven Cytokine Production or Toll-Like Receptor 4 Endocytosis.Frontiers in immunology · 2017Article
- Article
- Development and Characterization of New Species Cross-Reactive Anti-Sialoadhesin Monoclonal Antibodies.Antibodies (Basel, Switzerland) · 2016Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An inhibitory rat mAb, SER-4, has been raised to the mouse macrophage (M phi)-restricted hemagglutinin, sheep erythrocyte receptor (SER), which binds unopsonized sheep erythrocytes through recognition of sialylated glycoconjugates. This receptor was originally defined on mouse resident bone marrow M phi where it was implicated in adhesive interactions of these cells with proliferating hematopoietic cells. In the present study using mouse serum-induced thioglycollate-elicited peritoneal M phi (TPM) as a model system for SER expression, mAb SER-4 IgG2a completely blocked rosette formation at 1 microgram/ml. The inhibition was likely to be via steric hindrance rather than through a direct interaction with the putative sialic acid binding site of SER because F(ab')2 and Fab fragments of mAb SER-4 gave a maximum inhibition of 50-60% and 0% respectively, despite binding effectively to the SER-4 antigen (Ag). Immunoprecipitation and Western blotting experiments with cultured M phi or tissue extracts demonstrated that the Ag recognized by SER-4 mAb is a single chain molecule with an apparent Mr by SDS-PAGE of 185 x 10(3) (reduced) or 170 x 10(3) (non-reduced) and is distinct from members of the leukocyte common Ag family. Expression of SER and SER-4 Ag in culture were closely correlated and depended on the presence of mouse serum for optimal induction. Further evidence that the SER-4 Ag is functionally equivalent to SER was provided by immunocytochemistry in which the overall pattern of staining in tissues was consistent with previous rosetting experiments. In the bone marrow, expression of the SER-4 Ag was restricted to the resident bone marrow M phi population with no expression on monocytes. High expression was also observed on stromal M phi within the subcapsular sinus and medullary cords in lymph nodes and on marginal metallophils in the spleen. These results therefore confirm that SER is a novel M phi-restricted receptor whose distribution and properties indicate a role in cellular interactions in hematopoietic and lymphoid tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.